References
Reid C, Griffiths CEM (2020) Psoriasis and treatment: past, present and future aspects. Acta Derm Venereol 100(3):69–79
Kaushik SB, Lebwohl MG (2019) Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 80(1):27–40. https://doi.org/10.1016/j.jaad.2018.06.057
Plachouri KM, Georgiou S (2019) Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis. Int J Dermatol 58(9):1008–1013
Vaengebjerg S, Skov L, Egeberg A, Loft ND (2020) Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol 156(4):421–429
Geller S, Haoming X, Lebwohl M, Nardone B, Lacouture M, Kheterpal M (2018) Malignancy risk and recurrence with psoriasis and its treatments: a concise update. Am J Clin Dermatol 19(3):363–375
Valenti M, Pavia G, Gargiulo L, Facheris P, Sanna F, Borroni R et al (2021) Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population. J Dermatolog Treat 33(3):1638–1642
Bellinato F, Gisondi P, Maurelli M, Girolomoni G (2021) IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review. Dermatol Ther 34(2):1–6
Carrascosa JM, Puig L, Romero IB, Salgado-Boquete L, del Alcázar E, Lencina JJA et al (2022) Actualización práctica de las recomendaciones del grupo de psoriasis de la Academia Española de dermatología y venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo. Actas Dermosifiliogr 113(6):583–609
Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W et al (2020) British association of dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol 183(4):628–637
Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ (2021) Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol 22(4):425–42. https://doi.org/10.1007/s40257-021-00603-w
Author information
Authors and Affiliations
Contributions
JOA, LRF-F and JC-MS designed the study and wrote the main manuscrip text. JCH-R, RB-N and MM-A conducted data research. AJD-R prepared the figures. All authors reviewed and approved the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Dra Rodríguez Fernández-Freire served as a consultant and speaker for AbbVie Laboratories, Janssen Pharmaceuticals Inc, MSD, Pfizer-Wyeth, Novartis, Celgene, Almirall SA, USB, Lilly and Leo-Pharma. The rest of the authors declare no conflicts of interests regarding this study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ortiz Álvarez, J., Rodríguez Fernández-Freire, L., Hernández-Rodríguez, J.C. et al. Efficacy and safety of biological therapy in patients with psoriasis and recent neoplasia: experience in real single-center clinical practice. Arch Dermatol Res 315, 1045–1048 (2023). https://doi.org/10.1007/s00403-022-02443-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-022-02443-y